Heck Capital Advisors LLC Buys Shares of 193 Laboratory Co. of America Holdings (NYSE:LH)

Heck Capital Advisors LLC purchased a new position in Laboratory Co. of America Holdings (NYSE:LH) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 193 shares of the medical research company’s stock, valued at approximately $44,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Creative Planning grew its stake in Laboratory Co. of America by 14.7% in the 2nd quarter. Creative Planning now owns 12,854 shares of the medical research company’s stock worth $2,616,000 after acquiring an additional 1,646 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Laboratory Co. of America by 19.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,657 shares of the medical research company’s stock worth $1,152,000 after purchasing an additional 913 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Laboratory Co. of America in the second quarter valued at $2,268,000. AMF Tjanstepension AB lifted its position in Laboratory Co. of America by 37.0% during the third quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock worth $19,232,000 after buying an additional 23,221 shares during the period. Finally, Czech National Bank boosted its stake in Laboratory Co. of America by 6.5% in the 3rd quarter. Czech National Bank now owns 17,104 shares of the medical research company’s stock worth $3,822,000 after buying an additional 1,040 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LH has been the topic of several recent analyst reports. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Morgan Stanley increased their price target on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group dropped their price objective on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Piper Sandler increased their target price on Laboratory Co. of America from $235.00 to $240.00 and gave the stock a “neutral” rating in a research report on Monday, October 28th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $275.00 price target (up previously from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $261.77.

Laboratory Co. of America Trading Down 0.9 %

LH opened at $249.39 on Monday. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The stock has a market capitalization of $20.86 billion, a PE ratio of 48.24, a P/E/G ratio of 1.83 and a beta of 1.06. The firm’s fifty day moving average price is $236.02 and its 200 day moving average price is $228.63.

Laboratory Co. of America Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.15%. Laboratory Co. of America’s payout ratio is 55.71%.

Insider Buying and Selling

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the sale, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the sale, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,572 shares of company stock worth $5,915,209. Corporate insiders own 0.85% of the company’s stock.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.